

CLAIMS

1. Use of an eIF4E binding agent in therapy.

5 2. Use according to claim 1 for the induction of  
programmed cell death.

3. Use according to either of claims 1 or 2 wherein  
the agent is a peptide or peptidemimetic.

10 4. Use according to claim 3 wherein said peptide  
comprises the sequence:

YxxxxLØ

wherein x is a variable amino acid and Ø is Leu, Met or  
Phe;

15 or a fragment or derivative thereof.

5. Use according to claim 4 wherein said peptide  
comprises the sequence:

(K/R)xxYxxx(F/Q)L(L/M).

20

6. Use according to claim 5 wherein said peptide  
comprises the sequence:

KKRYDREFLLGF,

RVRYSDDL, or

25 RIIYDRKL(L/M).

7. Use according to any of claims 3 - 6 wherein said  
peptide is 7 - 25 amino acids in length.

8. Use of a peptide comprising sequence:

YxxxxLØ wherein x is a variable amino acid and Ø is Leu, Met or Phe;

or fragment or derivate thereof in the manufacture of a medicament for therapy, more particularly for inducing cell death.

9. Use according to claim 8 wherein the medicament is used to induce cell death in tumour cells.

10. Use of a polynucleotide fragment encoding a peptide comprising sequence:

YxxxxLØ wherein x is a variable amino acid and Ø is Leu, Met or Phe.